Status:
COMPLETED
A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).
Lead Sponsor:
GlaxoSmithKline
Conditions:
Rhinitis, Allergic, Perennial
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 ...
Detailed Description
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg f...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of perennial allergic rhinitis (PAR).
- Must comply with study procedures and be literate.
- Exclusion criteria:
- Significant concomitant medical conditions.
- Use of corticosteroids.
- Use of allergy medications and some other medications during the study.
- Current tobacco use.
- Clinically significant abnormal ECG or laboratory abnormality.
Exclusion
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
288 Patients enrolled
Trial Details
Trial ID
NCT00103454
Start Date
January 1 2005
End Date
May 1 2005
Last Update
September 19 2016
Active Locations (49)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
2
GSK Investigational Site
Los Angeles, California, United States, 90025
3
GSK Investigational Site
Mission Viejo, California, United States, 92691
4
GSK Investigational Site
Orange, California, United States, 92868